2007
DOI: 10.1016/j.bbrc.2007.08.012
|View full text |Cite
|
Sign up to set email alerts
|

Ginger ingredients reduce viability of gastric cancer cells via distinct mechanisms

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
84
1

Year Published

2008
2008
2022
2022

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 127 publications
(92 citation statements)
references
References 23 publications
2
84
1
Order By: Relevance
“…3-Nonen-2-one disrupted the distribution of tubulin (Fig. 2) in a manner similar to that observed in the cells treated with 6-shogaol [9], while nonan-2-one and 3-nonene did not (Fig. 2).…”
Section: Resultssupporting
confidence: 76%
See 2 more Smart Citations
“…3-Nonen-2-one disrupted the distribution of tubulin (Fig. 2) in a manner similar to that observed in the cells treated with 6-shogaol [9], while nonan-2-one and 3-nonene did not (Fig. 2).…”
Section: Resultssupporting
confidence: 76%
“…1A). Unlike 6-gingerol, we have previously shown that 6-shogaol damages microtubules, induces mitotic arrest and reduces the viability of gastric cancer cells (HGC-27 cells, IC50 = 6 lM; AGS cells, 6 lM; Kato cells, 10 lM), and that the administration of 6-shogaol suppresses the growth of tumor transplanted to nude mice [9]. 6-Shogaol contains the structure -C‚C-near the carbonyl group, while 6-gingerol does not.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…More recent studies have suggested that gingerols exhibit preventive activity against cancers of the skin [10] , pancreas [11] , gastrointestinal tract [12] , colon [13] , and breast [14] . Ginger can also effectively prevent nausea induced by cancer treatment [15] .…”
Section: Introductionmentioning
confidence: 99%
“…Remarkably, 10-gingerol was about 50-fold more potent (IC50 = 12 versus 670 µM, respectively) than 6-gingerol [39]. Ginger and its bioactive molecules are effective in regulatory the degree of colorectal, gastric, ovarian, liver, skin, breast, and prostate cancers [40,[42][43][44][45][46][47]. Kim et al [45] have carried out an experiment in mouse models and administered Zerumbone orally and observed inhibition in a multiplicity of colonic adenocarcinomas through suppression of colonic inflammation in a dose-dependent manner.…”
Section: Anti-cancer Effectsmentioning
confidence: 99%